3-(hydroxymethyl)-2-phenylpyrazolo<1,5-a>pyridine | 127717-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(hydroxymethyl)-2-phenylpyrazolo<1,5-a>pyridine
• 英文别名: (2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)methanol；(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)methanol
• CAS: 127717-25-3
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: NUFJFBVKAJEKOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(hydroxymethyl)-2-phenylpyrazolo<1,5-a>pyridine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以86%的产率得到bis(2-phenylpyrazolo<1,5-a>pyrid-3-yl)methane
  参考文献：
  名称：

  Miki, Yasuyoshi; Nakamura, Noriko; Hachiken, Hiroko, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1739 - 1745

  摘要：

  DOI：
• 作为产物：
  描述：

  苯丙炔酸甲酯 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 3-(hydroxymethyl)-2-phenylpyrazolo<1,5-a>pyridine
  参考文献：
  名称：

  Miki, Yasuyoshi; Nakamura, Noriko; Hachiken, Hiroko, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1739 - 1745

  摘要：

  DOI：

文献信息

• Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
  作者：Michael D. Shultz、Xueying Cao、Christine H. Chen、Young Shin Cho、Nicole R. Davis、Joe Eckman、Jianmei Fan、Alex Fekete、Brant Firestone、Julie Flynn、Jack Green、Joseph D. Growney、Mats Holmqvist、Meier Hsu、Daniel Jansson、Lei Jiang、Paul Kwon、Gang Liu、Franco Lombardo、Qiang Lu、Dyuti Majumdar、Christopher Meta、Lawrence Perez、Minying Pu、Tim Ramsey、Stacy Remiszewski、Suzanne Skolnik、Martin Traebert、Laszlo Urban、Vinita Uttamsingh、Ping Wang、Steven Whitebread、Lewis Whitehead、Yan Yan-Neale、Yung-Mae Yao、Liping Zhou、Peter Atadja

  DOI：10.1021/jm200388e

  日期：2011.7.14

  Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent. HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree, of pharmacophore homology between these two targets was discovered. This, similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.
• MIKI, YASUYOSHI;NAKAMURA, NORIKO;HACHIKEN, HIROKO;TAKEMURA, SHOJI, J. HETEROCYCL. CHEM., 26,(1989) N, C. 1739-1745
  作者：MIKI, YASUYOSHI、NAKAMURA, NORIKO、HACHIKEN, HIROKO、TAKEMURA, SHOJI

  DOI：——

  日期：——
• Miki, Yasuyoshi; Nakamura, Noriko; Hachiken, Hiroko, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1739 - 1745
  作者：Miki, Yasuyoshi、Nakamura, Noriko、Hachiken, Hiroko、Takemura, Shoji

  DOI：——

  日期：——